Hemodialysis does not alter in vitro hepatic CYP3A4 and CYP2D6 metabolic activity in uremic serum

Brian S. Decker, Kalisha D. O'Neill, Mary A. Chambers, James E. Slaven, Zhangsheng Yu, David R. Jones, Sharon M. Moe

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

There is a paucity of studies evaluating the change in liver metabolism in subjects receiving hemodialysis. The purpose of this study was to compare the effect of uremic toxins on hepatic cytochrome P450 (CYP)3A4 and CYP2D6 metabolism before and after a 4-hour hemodialysis session. Midazolam and dextromethorphan were incubated with uremic serum collected from subjects before and after the 4-hour hemodialysis session. Analysis and quantification of the 1′-OH-midazolam and 4-OH-midazolam and dextrorphan metabolites were performed by high-pressure liquid chromatography/mass spectrometry. Statistical analysis using the Student's t-test (paired) was used to compare the amount of metabolite formed. The mean amount of 1′-OH-midazolam, 4-OH-midazolam, and dextrorphan metabolites formed before and after hemodialysis did not significantly differ. There was no significant difference in CYP3A4 and CYP2D6 metabolic activity in uremic serum before and after hemodialysis.

Original languageEnglish (US)
Pages (from-to)193-199
Number of pages7
JournalClinical Pharmacology: Advances and Applications
Volume5
DOIs
StatePublished - Dec 10 2013

Keywords

  • CYP2D6
  • CYP3A4
  • Hemodialysis
  • Metabolism
  • Uremia

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Hemodialysis does not alter in vitro hepatic CYP3A4 and CYP2D6 metabolic activity in uremic serum'. Together they form a unique fingerprint.

  • Cite this